MTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Tingting ^a   Zhao, Yang ^a   Wang, Hao ^b   Li, Yang ^a   Shao, Lijuan ^a,c   Wang, Ruoyu ^c   Lu, Jun ^d   Yang, Zhongzhou ^e   Wang, Junjie ^b   Zhao, Yong ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c DALIAN UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ALLOGRAFT; ANIMAL; CELL COUNT; CELL DIFFERENTIATION; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GRAFT REJECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; METABOLISM; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION;

ALLOGRAFTS; ANIMALS; CELL COUNT; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GRAFT REJECTION; IMMUNOSUPPRESSION; MICE; MICE, KNOCKOUT; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TOR SERINE-THREONINE KINASES;

EID: 84956606229     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20250     Document Type: Article

References (61)

1. Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood 111, 4233-4244 (2008).
2. Lees, J. R., Azimzadeh, A. M., Bromberg, J. S. Myeloid derived suppressor cells in transplantation. Curr Opin Immunol 23, 692-697 (2011).
3. Wu, T., Zhao, Y., Zhao, Y. The roles of myeloid-derived suppressor cells in transplantation. Expert review of clinical immunology 10, 1385-1394 (2014).
4. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166, 678-689 (2001).
5. Mandruzzato, S. et al. IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182, 6562-6568 (2009).
6. Youn, J. I., Nagaraj, S., Collazo, M., Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181, 5791-5802 (2008).
7. Gabrilovich, D. I., Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174 (2009).
8. Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer. Nature medicine 13, 828-835 (2007).
9. De Wilde, V. et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. American Journal of Transplantation 9, 2034-2047 (2009).
10. Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118, 5498-5505 (2011).
11. Li, H., Han, Y., Guo, Q., Zhang, M., Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182, 240-249 (2009).
12. Baban, B. et al. Physiologic control of IDO competence in splenic dendritic cells. J Immunol 187, 2329-2335 (2011).
13. Condamine, T., Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32, 19-25 (2011).
14. Wu, T. et al. Smad3-deficient CD11b(+ )Gr1(+ ) myeloid-derived suppressor cells prevent allograft rejection via the nitric oxide pathway. J Immunol 189, 4989-5000 (2012).
15. Lim, W. H. et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 14, 2106-2119 (2014).
16. Beck, J. T., Ismail, A., Tolomeo, C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer treatment reviews 40, 980-989 (2014).
17. Yori, J. L. et al. Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer research 74, 4762-4771 (2014).
18. Zardavas, D., Fumagalli, D., Loi, S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER +/HER2-) breast cancers? Current opinion in oncology 24, 623-634 (2012).
19. Wu, T. et al. Immunosuppressive drugs on inducing Ag-specific CD4(+ )CD25(+ )Foxp3(+ ) Treg cells during immune response in vivo. Transplant immunology 27, 30-38 (2012).
20. Waickman, A. T., Powell, J. D. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunological reviews 249, 43-58 (2012).
21. Qu, Y. et al. The effect of immunosuppressive drug rapamycin on regulatory CD4 + CD25 + Foxp3 + T cells in mice. Transplant immunology 17, 153-161 (2007).
22. Saemann, M. D., Haidinger, M., Hecking, M., Horl, W. H., Weichhart, T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 9, 2655-2661 (2009).
23. Haidinger, M. et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 185, 3919-3931 (2010).
24. Weichhart, T. et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29, 565-577 (2008).
25. Zhu, L. et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nature communications 5, 4696 (2014).
26. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22, 238-244 (2010).
27. Chou, Y. Y., Gao, J. I., Chang, S. F., Chang, P. Y., Lu, S. C. Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2. FEBS J 278, 85-96 (2011).
28. Fox, R. et al. PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J 26, 505-515 (2007).
29. Yang, T. Y., Sun, Y., Langnas, A. N., Zhao, Y. Prolongation of allogeneic skin graft survival by injection of anti-Ly49A monoclonal antibody YE1/48. Clin Immunol 106, 148-154 (2003).
30. Frias, M. A. et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Current biology: CB 16, 1865-1870 (2006).
31. Jacinto, E. et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137 (2006).
32. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168 (2006).
33. Chen, H. et al. Disruption of TSC1/2 signaling complex reveals a checkpoint governing thymic CD4 + CD25 + Foxp3 + regulatory T-cell development in mice. FASEB J 27, 3979-3990 (2013).
34. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168, 689-695 (2002).
35. Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008).
36. Rees, D. D., Palmer, R. M., Hodson, H. F., Moncada, S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96, 418-424 (1989).
37. Pernicova, I., Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10, 143-156 (2014).
38. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., McGuire, D. K. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312, 2668-2675 (2014).
39. Saeedi, R. et al. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol 294, H2497-2506 (2008).
40. Cheong, J. H. et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10, 2350-2362 (2011).
41. Pierotti, M. A. et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32, 1475-1487 (2013).
42. Janzer, A. et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci USA 111, 10574-10579 (2014).
43. Kirsch, A. H. et al. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. American journal of physiology. Renal physiology 303, F569-575 (2012).
44. Weichhart, T. et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 117, 4273-4283 (2011).
45. Brouard, S. et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 10, 2604-2614 (2010).
46. Dugast, A. S. et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 180, 7898-7906 (2008).
47. Zhang, W., Liang, S., Wu, J., Horuzsko, A. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b + Gr1 + myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation 86, 1125-1134 (2008).
48. Inoki, K., Kim, J., Guan, K. L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annual review of pharmacology and toxicology 52, 381-400 (2012).
49. Laplante, M., Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
50. Warburg, O., Wind, F., Negelein, E. The Metabolism of Tumors in the Body. The Journal of general physiology 8, 519-530 (1927).
51. Calvano, S. E. et al. A network-based analysis of systemic inflammation in humans. Nature 437, 1032-1037 (2005).
52. Everts, B. et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120, 1422-1431 (2012).
53. Wang, Y. et al. Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci USA 110, E4894-4903 (2013).
54. Goodarzi, M. O., Bryer-Ash, M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes, obesity & metabolism 7, 654-665 (2005).
55. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 108, 1167-1174 (2001).
56. Tanaka, T., Sue, F., Morimura, H. Feed-forward activation and feed-back inhibition of pyruvate kinase type L of rat liver. Biochemical and biophysical research communications 29, 444-449 (1967).
57. Vasamsetti, S. B. et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64, 2028-2041 (2015).
58. Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32, 790-802 (2010).
59. Qu, Y. et al. 2-Gy whole-body irradiation significantly alters the balance of CD4 + CD25-T effector cells and CD4 + CD25 + Foxp3 + T regulatory cells in mice. Cellular & molecular immunology 7, 419-427 (2010).
60. Angulo, I. et al. Nitric oxide-producing CD11b(+ )Ly-6G(Gr-1)(+ )CD31(ER-MP12)(+ ) cells in the spleen of cyclophosphamidetreated mice: implications for T-cell responses in immunosuppressed mice. Blood 95, 212-220 (2000).
61. Hou, Y. et al. The inhibitory effect of IFN-gamma on protease HTRA1 expression in rheumatoid arthritis. J Immunol 193, 130-138 (2014).